A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Latest Information Update: 18 Mar 2025
Price :
$35 *
At a glance
- Drugs Tetrodotoxin (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors WEX Pharmaceuticals
- 12 Mar 2025 According to a Dogwood Therapeutics media release, Dosing of the first patient anticipated in the near term.
- 18 Feb 2025 According to ClinicalTrials.gov, this Study was terminated due to lack of funding to continue the study.
- 18 Feb 2025 Status changed from recruiting to discontinued.